Kolte B, Nubel U
J Antimicrob Chemother. 2024; 79(6):1320-1328.
PMID: 38598696
PMC: 11144481.
DOI: 10.1093/jac/dkae101.
Etifa P, Rodriguez C, Harmanus C, Sanders I, Sidorov I, Mohammed O
Antibiotics (Basel). 2023; 12(3).
PMID: 36978302
PMC: 10044524.
DOI: 10.3390/antibiotics12030435.
Kim K, Gluck M
Clin Endosc. 2019; 52(2):137-143.
PMID: 30909689
PMC: 6453848.
DOI: 10.5946/ce.2019.009.
Baines S, Wilcox M
Antibiotics (Basel). 2016; 4(3):267-98.
PMID: 27025625
PMC: 4790285.
DOI: 10.3390/antibiotics4030267.
Wenzler E, Mulugeta S, Danziger L
Antibiotics (Basel). 2016; 4(2):198-215.
PMID: 27025621
PMC: 4790327.
DOI: 10.3390/antibiotics4020198.
Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea.
Lenoir-Wijnkoop I, Nuijten M, Craig J, Butler C
Front Pharmacol. 2014; 5:13.
PMID: 24596556
PMC: 3926519.
DOI: 10.3389/fphar.2014.00013.
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G, Tanha J
Toxins (Basel). 2011; 2(5):998-1018.
PMID: 22069622
PMC: 3153223.
DOI: 10.3390/toxins2050998.
Current Treatment Options for Severe Clostridium difficile-associated Disease.
Shen E, Surawicz C
Gastroenterol Hepatol (N Y). 2011; 4(2):134-9.
PMID: 21904490
PMC: 3088840.
Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.
Choi H, Kim K, Lee S, Lee S
J Korean Med Sci. 2011; 26(7):859-64.
PMID: 21738336
PMC: 3124713.
DOI: 10.3346/jkms.2011.26.7.859.
Clostridium difficile--a moving target.
Tillotson G, Tillotson J
F1000 Med Rep. 2011; 3:6.
PMID: 21654927
PMC: 3096886.
DOI: 10.3410/M3-6.
Metronidazole resistance in Clostridium difficile is heterogeneous.
Pelaez T, Cercenado E, Alcala L, Marin M, Martin-Lopez A, Martinez-Alarcon J
J Clin Microbiol. 2008; 46(9):3028-32.
PMID: 18650353
PMC: 2546748.
DOI: 10.1128/JCM.00524-08.
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.
Al-nassir W, Sethi A, Li Y, Pultz M, Riggs M, Donskey C
Antimicrob Agents Chemother. 2008; 52(7):2403-6.
PMID: 18443120
PMC: 2443881.
DOI: 10.1128/AAC.00090-08.
A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.
Peppe J, Porzio A, Davidson D
Br J Clin Pharmacol. 2008; 66(1):102-9.
PMID: 18341677
PMC: 2485258.
DOI: 10.1111/j.1365-2125.2008.03151.x.
Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay.
Musher D, Manhas A, Jain P, Nuila F, Waqar A, Logan N
J Clin Microbiol. 2007; 45(8):2737-9.
PMID: 17567791
PMC: 1951241.
DOI: 10.1128/JCM.00686-07.
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
Bourgault A, Lamothe F, Loo V, Poirier L
Antimicrob Agents Chemother. 2006; 50(10):3473-5.
PMID: 17005836
PMC: 1610058.
DOI: 10.1128/AAC.00479-06.
Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial.
Fordtran J
Proc (Bayl Univ Med Cent). 2006; 19(1):3-12.
PMID: 16424922
PMC: 1325276.
DOI: 10.1080/08998280.2006.11928114.
Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.
Ho J, Greco A, Rupnik M, Ng K
Proc Natl Acad Sci U S A. 2005; 102(51):18373-8.
PMID: 16344467
PMC: 1317924.
DOI: 10.1073/pnas.0506391102.
